Cardax, Inc. (CDXI)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Cardax, Inc. (CDXI) trades at $0.00 with AI Score 51/100 (Grade B). Cardax, Inc. is a biopharmaceutical company focused on developing and commercializing dietary supplements and pharmaceuticals targeting inflammation and oxidative stress. Market cap: $80, Sector: Healthcare.
Last analyzed: Mar 16, 2026Analyst Coverage for CDXI: CDXI does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates CDXI against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
CDXI: 2/7 perspectives are bearish. Dominant signal: Ken Griffin bearish.
Cardax, Inc. (CDXI) Healthcare & Pipeline Overview
Cardax, Inc. is a biopharmaceutical company developing and commercializing dietary supplements and pharmaceuticals targeting inflammatory health. Its primary product, ZanthoSyn, an astaxanthin supplement, is sold through e-commerce and wholesale channels. The company's pharmaceutical pipeline includes CDX-101 for cardiovascular inflammation and CDX-301 for macular degeneration, positioning it within the competitive biotechnology landscape.
What Is the Investment Thesis for CDXI?
Cardax, Inc. presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's focus on inflammation and oxidative stress, coupled with its astaxanthin-based product line, aligns with growing consumer and medical interest in natural compounds for health and disease management. Key value drivers include the successful commercialization of ZanthoSyn, which currently has a gross margin of 63.6%, and the advancement of CDX-101 and CDX-301 through clinical trials. Growth catalysts include potential partnerships for pharmaceutical development and regulatory approvals for its drug candidates. However, the company's negative profit margin of -938.0% and reliance on e-commerce and wholesale channels for ZanthoSyn sales pose significant risks. The company's small market capitalization of $0.00B and high beta of -13.76 indicate substantial volatility. Successful navigation of regulatory hurdles and securing additional funding will be critical for Cardax to realize its potential.
Based on FMP financials and quantitative analysis
CDXI Key Highlights
- Gross Margin of 63.6% on ZanthoSyn sales indicates strong pricing power and efficient production.
- Development of CDX-101 targets severe hypertriglyceridemia, a significant unmet medical need in cardiovascular health.
- CDX-301 is being developed for macular degeneration, addressing a growing market driven by an aging population.
- ZanthoSyn is sold through e-commerce and wholesale channels, providing diversified revenue streams.
- The company has a small team of 10 employees, suggesting a lean operational structure.
Who Are CDXI's Competitors?
CDXI is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ELOX Eloxx Pharmaceuticals, Inc. | $14.15 | +11.99% | $107.20M | 51 |
| SNDX Syndax Pharmaceuticals, Inc. | $18.25 | +1.90% | 2B | 79 |
| ANAB AnaptysBio, Inc. | $56.07 | +3.37% | 3B | 79 |
| ABCL AbCellera Biologics Inc. | $5.24 | -0.57% | 2B | 76 |
| CGEN Compugen Ltd. | $2.02 | -0.98% | $191.00M | 76 |
| NWPHF Newron Pharmaceuticals S.p.A. | $20.00 | +0.00% | $416.12M | 68 |
| DAWN Day One Biopharmaceuticals, Inc. | $21.53 | +0.00% | 3B | 68 |
| CELU Celularity Inc. | $0.73 | +0.44% | $17.56M | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are CDXI's Key Strengths?
- Proprietary astaxanthin formulation (ZanthoSyn).
- Focus on inflammation and oxidative stress.
- Development pipeline of pharmaceutical candidates.
- Existing e-commerce and wholesale distribution channels.
What Are CDXI's Weaknesses?
- Small market capitalization.
- Negative profit margin.
- Limited financial resources.
- Reliance on a small number of products.
What Could Drive CDXI Stock Higher?
- Results from clinical trials for CDX-101.
- Results from clinical trials for CDX-301.
- Expansion of ZanthoSyn distribution channels.
- Potential partnerships with pharmaceutical companies.
- New product development in inflammatory health.
What Are the Key Risks for CDXI?
- Failure to obtain regulatory approvals for CDX-101 and CDX-301.
- Competition from established pharmaceutical companies.
- Limited financial resources.
- Dependence on a small number of products.
- Adverse events associated with its products.
What Are the Growth Opportunities for CDXI?
- Expansion of ZanthoSyn Distribution: Cardax can expand its distribution channels for ZanthoSyn beyond e-commerce and wholesale to include retail pharmacies and healthcare providers. This broader reach could significantly increase sales volume and brand awareness. The global dietary supplements market is expected to grow, presenting a substantial opportunity for ZanthoSyn to capture a larger market share. Timeline: Ongoing.
- Advancement of CDX-101 Clinical Trials: Successful completion of clinical trials for CDX-101 would represent a major milestone for Cardax, potentially leading to regulatory approval and commercialization. The market for cardiovascular drugs is substantial, and a novel treatment for severe hypertriglyceridemia could generate significant revenue. The timeline for clinical trials and regulatory approval is estimated to be several years. Market size: Multi-billion dollar market.
- Development of CDX-301 for Macular Degeneration: The development of CDX-301 offers Cardax an opportunity to address the growing market for macular degeneration treatments. As the global population ages, the prevalence of macular degeneration is expected to increase, driving demand for effective therapies. Successful clinical trials and regulatory approval could position CDX-301 as a valuable asset. Timeline: Several years for clinical trials and approval. Market size: Billions of dollars.
- Strategic Partnerships with Pharmaceutical Companies: Cardax can pursue strategic partnerships with larger pharmaceutical companies to accelerate the development and commercialization of its pharmaceutical candidates. These partnerships could provide access to funding, expertise, and distribution networks. The pharmaceutical industry is actively seeking innovative therapies, making strategic partnerships a viable growth strategy. Timeline: Ongoing.
- Expansion into New Therapeutic Areas: Cardax can leverage its expertise in inflammation and oxidative stress to develop new products and therapies for other chronic diseases. This diversification could reduce the company's reliance on its existing product pipeline and create new revenue streams. The market for chronic disease treatments is vast, offering numerous opportunities for Cardax to expand its focus. Timeline: Long-term.
What Opportunities Does CDXI Have?
- Expansion of ZanthoSyn distribution.
- Successful clinical trials for CDX-101 and CDX-301.
- Strategic partnerships with pharmaceutical companies.
- Expansion into new therapeutic areas.
What Threats Does CDXI Face?
- Competition from established pharmaceutical companies.
- Regulatory hurdles for pharmaceutical approvals.
- Changes in consumer preferences for dietary supplements.
- Potential adverse events associated with its products.
What Are CDXI's Competitive Advantages?
- Proprietary formulations of astaxanthin and zeaxanthin.
- Focus on enhanced absorption and purity of ingredients.
- Development of pharmaceutical candidates targeting specific diseases.
- Established e-commerce and wholesale distribution channels for ZanthoSyn.
What Does CDXI Do?
Cardax, Inc., based in Honolulu, Hawaii, is a biopharmaceutical company dedicated to creating and marketing innovative dietary supplements and pharmaceuticals designed to combat chronic diseases driven by inflammation and oxidative stress. The company's flagship product, ZanthoSyn, is an inflammatory supplement formulated with astaxanthin, known for its enhanced absorption and purity. ZanthoSyn is currently available through e-commerce platforms and wholesale distribution channels. Founded with the vision of harnessing the therapeutic potential of natural compounds, Cardax is also actively developing a pipeline of pharmaceutical candidates. CDX-101, one of the company's leading pharmaceutical assets, is an astaxanthin-based formulation targeting cardiovascular inflammation and dyslipidemia, with a specific focus on severe hypertriglyceridemia. The company is also advancing CDX-301, a zeaxanthin-based pharmaceutical candidate intended for the treatment of macular degeneration. These pharmaceutical programs represent Cardax's strategic expansion into addressing significant unmet medical needs with innovative, science-backed solutions. Cardax's business model encompasses both the direct-to-consumer sale of dietary supplements and the development of prescription pharmaceuticals, allowing the company to generate revenue while simultaneously pursuing long-term growth opportunities in the pharmaceutical market. With a small team of 10 employees, Cardax is focused on efficiently advancing its product pipeline and expanding its market reach.
What Products and Services Does CDXI Offer?
- Develops dietary supplements for inflammatory health.
- Commercializes dietary supplements through e-commerce and wholesale channels.
- Develops pharmaceutical candidates for chronic diseases.
- Focuses on inflammation and oxidative stress.
- Utilizes astaxanthin and zeaxanthin in its products.
- Targets cardiovascular inflammation and macular degeneration.
How Does CDXI Make Money?
- Develops and patents proprietary formulations.
- Sells ZanthoSyn directly to consumers through e-commerce.
- Distributes ZanthoSyn through wholesale channels.
- Seeks partnerships for pharmaceutical development.
What Industry Does CDXI Operate In?
Cardax, Inc. operates within the biotechnology and dietary supplement industries, both characterized by rapid innovation and evolving consumer preferences. The global biotechnology market is projected to reach trillions of dollars by 2026, driven by advancements in drug discovery and personalized medicine. The dietary supplement market is also experiencing steady growth, fueled by increasing consumer awareness of preventative healthcare. Cardax competes with both established pharmaceutical companies and smaller biotech firms in the development of novel therapeutics. The company's success depends on its ability to differentiate its products, navigate regulatory pathways, and secure strategic partnerships.
Who Are CDXI's Key Customers?
- Consumers seeking inflammatory health supplements.
- Wholesale distributors of dietary supplements.
- Potential pharmaceutical partners.
- Patients with cardiovascular inflammation and dyslipidemia.
- Patients with macular degeneration.
CDXI Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
CDXI Latest News
No recent news available for CDXI.
CDXI Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for CDXI.
Price Targets
Wall Street price target analysis for CDXI.
CDXI MoonshotScore
What does this score mean?
The MoonshotScore rates CDXI's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: David G. Watumull
CEO
David G. Watumull serves as the CEO of Cardax, Inc., leading a team of 10 employees. Information regarding his detailed career history, education, and previous roles is not available. His leadership is focused on guiding the company's strategic direction, overseeing the development and commercialization of its products, and managing its overall operations. He is responsible for driving the company's growth and achieving its financial objectives.
Track Record: Due to limited information, David G. Watumull's specific achievements, strategic decisions, and company milestones under his leadership cannot be comprehensively assessed. His focus is on advancing the company's pharmaceutical pipeline and expanding the market reach of ZanthoSyn. Further information is needed to evaluate his long-term impact on Cardax, Inc.
CDXI OTC Market Information
The OTC Other tier, where Cardax trades, represents the lowest tier of the OTC market. Companies in this tier often have limited or no financial disclosure, making it difficult for investors to assess their financial health and operational performance. Unlike companies listed on major exchanges like the NYSE or NASDAQ, OTC Other companies do not have to meet minimum listing standards, such as minimum share price or market capitalization requirements. This lack of regulation and oversight increases the risk associated with investing in these companies.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure increases the risk of investing in CDXI.
- Low trading volume and liquidity can lead to price volatility.
- Lack of regulatory oversight on the OTC Other tier.
- Potential for fraud or manipulation in the OTC market.
- Difficulty in obtaining reliable information about the company.
- Verify the company's registration and legal standing.
- Review available financial statements and disclosures.
- Assess the company's management team and their experience.
- Evaluate the company's business model and competitive landscape.
- Analyze the company's capital structure and funding sources.
- Monitor trading volume and price activity.
- Consult with a qualified financial advisor.
- Development of pharmaceutical candidates (CDX-101 and CDX-301).
- Commercialization of ZanthoSyn through e-commerce and wholesale channels.
- Focus on scientific research and development.
- Company has been in operation for several years.
Common Questions About CDXI (Healthcare)
What does Cardax, Inc. do?
Cardax, Inc. is a biopharmaceutical company that develops and commercializes dietary supplements and pharmaceutical candidates focused on inflammatory health and chronic diseases driven by inflammation and oxidative stress. Their primary product, ZanthoSyn, is an astaxanthin-based supplement sold through e-commerce and wholesale channels. The company is also developing CDX-101 for cardiovascular inflammation and CDX-301 for macular degeneration, aiming to address significant unmet medical needs with innovative, science-backed solutions in the healthcare sector.
What are the main risks for CDXI?
The main risks for Cardax, Inc. include its small market capitalization, negative profit margin, and limited financial resources. The company faces competition from established pharmaceutical companies and regulatory hurdles for pharmaceutical approvals. Additionally, there are risks associated with changes in consumer preferences for dietary supplements and potential adverse events associated with its products. Investing in CDXI involves significant risks due to its OTC listing and limited financial disclosure.
What are the key factors to evaluate for CDXI?
Cardax, Inc. (CDXI) holds an AI score of 51/100 (moderate). Not financial advice.
How frequently does CDXI data refresh on this page?
CDXI prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven CDXI's recent stock price performance?
Cardax, Inc. (CDXI) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary astaxanthin formulation (ZanthoSyn). See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider CDXI overvalued or undervalued right now?
Valuing Cardax, Inc. (CDXI) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying CDXI?
Before investing in Cardax, Inc. (CDXI), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding CDXI to a portfolio?
Key strength of Cardax, Inc. (CDXI): Proprietary astaxanthin formulation (ZanthoSyn). Weigh rewards against risks and diversify. Not financial advice.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available on CEO track record.
- OTC market data may be less reliable than major exchanges.
- AI analysis pending, limiting comprehensive insights.